CLVT,CNTA Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.04
Percentage change -0.98	%

Peers: SPGI TRI FDS VRSK MSCI IHS MORN DNB RELX IQV

| Held by: VXF AVUV DFAT SCHA IWR DFAS SCHM IWD IYW DFAC

Index	-	P/E	-	EPS (ttm)	-0.97	Insider Own	41.77%	Shs Outstand	691.40M	Perf Week	-1.95%
Market Cap	2.79B	Forward P/E	5.79	EPS next Y	0.70	Insider Trans	1.18%	Shs Float	402.75M	Perf Month	-17.92%
Income	-668.00M	PEG	-	EPS next Q	0.12	Inst Own	65.25%	Short Float	10.19%	Perf Quarter	-29.55%
Sales	2.56B	P/S	1.09	EPS this Y	-11.22%	Inst Trans	-1.25%	Short Ratio	7.73	Perf Half Y	-39.40%
Book/sh	7.43	P/B	0.54	EPS next Y	7.41%	ROA	-5.26%	Short Interest	41.03M	Perf Year	-43.08%
Cash/sh	0.43	P/C	9.44	EPS next 5Y	1.98%	ROE	-11.44%	52W Range	4.00 - 7.77	Perf YTD	-20.67%
Dividend Est.	-	P/FCF	8.26	EPS past 5Y	-0.40%	ROI	-6.88%	52W High	-48.13%	Beta	1.46
Dividend TTM	-	Quick Ratio	0.87	Sales past 5Y	23.24%	Gross Margin	37.57%	52W Low	0.76%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	0.87	EPS Y/Y TTM	34.70%	Oper. Margin	9.11%	RSI (14)	28.86	Volatility	5.85% 5.99%
Employees	12000	Debt/Eq	0.89	Sales Y/Y TTM	-2.74%	Profit Margin	-26.13%	Recom	2.36	Target Price	5.94
Option/Short	Yes / Yes	LT Debt/Eq	0.89	EPS Q/Q	78.97%	Payout	-	Rel Volume	0.62	Prev Close	4.07
Sales Surprise	0.43%	EPS Surprise	3.65%	Sales Q/Q	-3.03%	Earnings	Feb 19 BMO	Avg Volume	5.30M	Price	4.03
SMA20	-10.09%	SMA50	-18.03%	SMA200	-29.80%	Trades		Volume	994,116	Change	-0.98%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-06-24	Downgrade	William Blair	Outperform → Mkt Perform
Dec-15-23	Downgrade	Wells Fargo	Equal Weight → Underweight	$8
Oct-16-23	Upgrade	Jefferies	Hold → Buy	$10 → $8.50
Sep-08-23	Downgrade	Barclays	Equal Weight → Underweight	$8 → $7
Aug-25-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$9 → $8
Aug-07-23	Downgrade	BofA Securities	Neutral → Underperform	$10 → $6
Aug-04-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$15 → $8
Jun-13-23	Initiated	Oppenheimer	Outperform	$11
Mar-15-23	Resumed	BofA Securities	Neutral
Feb-06-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$11 → $12
Jul-13-22	Initiated	Wells Fargo	Overweight	$20
Feb-04-22	Downgrade	Citigroup	Buy → Neutral	$35 → $16
Feb-03-22	Downgrade	Barclays	Overweight → Equal Weight	$16
Dec-21-21	Resumed	Citigroup	Buy	$35
Dec-13-21	Resumed	Goldman	Buy	$30
Aug-16-21	Initiated	BofA Securities	Buy	$28
Aug-04-21	Resumed	RBC Capital Mkts	Outperform	$29
Mar-31-21	Initiated	Jefferies	Buy	$30
Mar-11-21	Resumed	Citigroup	Buy	$36
Mar-08-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$28

Show Previous Ratings

Today 04:00AM	Clarivate Reveals Top 100 Global Innovators 2025 (PR Newswire)
Feb-27-25 03:00AM	Clarivate Report Explores Opportunities for Innovation and Market Expansion in Latin America (PR Newswire)
Feb-25-25 07:34PM	Analyst Report: Clarivate Plc (Morningstar Research)
Feb-19-25 01:27PM	Analyst Report: Clarivate Plc (Morningstar Research)
06:00AM	Clarivate Reports Fourth Quarter and Full Year 2024 Results (PR Newswire)
03:00AM	Loading…
Feb-18-25 03:00AM	Clarivate Unveils Transformative Subscription-Based Access Strategy for Academia (PR Newswire)
Feb-10-25 09:30AM	Clarivate Recognized for Excellence in Trademark Business in the WTR 1000 2025 (PR Newswire)
Feb-05-25 03:00AM	Clarivate Selected by National and University Library in Zagreb, Croatia to Create a Unified National Library Platform (PR Newswire)
Feb-04-25 03:00AM	Clarivate Reveals Medtech Breakthroughs Driving Growth in Pulsed Field Ablation Market (PR Newswire)
Jan-30-25 03:00AM	Clarivate identifies top 50 universities powering global innovation (PR Newswire)
Jan-28-25 03:00AM	The British Library Selects Clarivate to Provide Library Services and Discovery Platforms (PR Newswire)
Jan-22-25 08:45AM	Clarivate to Report Fourth Quarter and Full Year 2024 Results on February 19, 2025 (PR Newswire)
Jan-16-25 09:55AM	Does Clarivate (CLVT) Have the Potential to Rally 29.13% as Wall Street Analysts Expect? (Zacks)
03:00AM	BioWorld by Clarivate Releases Comprehensive 2024 Year in Review (PR Newswire)
Jan-14-25 11:40AM	Post-marketing Pharmacovigilance and Medical Information Market Research 2024: Rising Adverse Drug Reactions (ADRs) and Expanding Use of Biologics and Specialty Drugs Fueling Growth - Forecast to 2034 (GlobeNewswire)
03:10AM	Loading…
03:10AM	Clarivate Launches DRG Fusion - A New Life Sciences Analytics Product Powered by Real-World Data (PR Newswire)
Jan-08-25 03:05AM	Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report (PR Newswire)
Dec-27-24 04:32AM	Why Clarivate Plc (CLVT) Is One of the Best Technology Penny Stocks to Buy According to Hedge Funds? (Insider Monkey)
Dec-16-24 08:00AM	Clarivate Announces New $500 Million Share Repurchase Authorization (PR Newswire) +7.24%
Dec-12-24 03:00AM	Clarivate Launches AI-Powered Patent Search Solution in Derwent (PR Newswire)
Nov-27-24 08:00AM	Clarivate and the Chinese Academy of Sciences Release Annual Collaborative Report to Identify 125 Research Fronts (PR Newswire)
03:00AM	Daikin Selects IPfolio from Clarivate (PR Newswire)
Nov-21-24 03:00AM	BioWorld by Clarivate Highlights Gaps in Women's Health Research and Investment in New Special Series (PR Newswire)
Nov-19-24 11:34PM	Analyst Report: Clarivate Plc (Morningstar Research) +5.41%
03:00AM	Clarivate Reveals Highly Cited Researchers 2024 List (PR Newswire)
Nov-18-24 03:00AM	New Report from Clarivate and Healthcare Executive Explores Mainland China's Biopharma Revolution and Increasing Global Influence (PR Newswire) +6.70%
Nov-14-24 06:46PM	Analyst Report: Clarivate Plc (Morningstar Research) -5.26%
Nov-13-24 03:00AM	Clarivate Healthcare Business Insights Unveils 2023 Revenue Cycle Award Winners (PR Newswire)
Nov-12-24 03:00AM	Clarivate Publishes 2023 Sustainability Report (PR Newswire)
Nov-07-24 08:35PM	Analyst Report: Clarivate Plc (Morningstar Research)
06:34AM	Loading…
06:34AM	Clarivate Faces Revenue Decline Amid Strategic Shift (TipRanks)
03:00AM	Clarivate Launches New Sustainability Research Solution (PR Newswire)
Nov-06-24 06:42PM	Analyst Report: Clarivate Plc (Morningstar Research) -27.16%
06:00AM	Clarivate Reports Third Quarter 2024 Results (PR Newswire)
Oct-30-24 10:01AM	Clarivate PLC (CLVT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-29-24 10:05AM	Silverchair to Acquire ScholarOne from Clarivate to Expand Investment & Innovation in Critical Publishing Technology (PR Newswire)
06:30AM	Thompson Street Portfolio Company Silverchair Announces Agreement to Acquire Scholarone (Business Wire)
Oct-16-24 08:30AM	Clarivate to Report Third Quarter 2024 Results on November 6, 2024 (PR Newswire)
Oct-15-24 03:00AM	Clarivate Repeats Success in Nobel Prize Predictions with Eight New Winners Identified by Citation Laureates Program (PR Newswire)
Oct-04-24 03:00AM	Clarivate in partnership with Abiquifi Announces Annual Summit LATAM Agenda (PR Newswire)
Sep-25-24 03:00AM	Clarivate Unveils Comprehensive Framework to Evaluate the Societal Impact of Research (PR Newswire)
Sep-24-24 03:00AM	New Clarivate Report Reveals Challenges and Trends Shaping IP Operations (PR Newswire)
Sep-23-24 03:00AM	Clarivate and Relatable Healthcare Forge Strategic Partnership to Transform Medtech Sales Contracting Process (PR Newswire)
Sep-19-24 06:30PM	Analyst Report: Clarivate Plc (Morningstar Research)
03:00AM	Clarivate Reveals Citation Laureates 2024 (PR Newswire)
Sep-18-24 03:00AM	Clarivate Launches Generative AI-Powered Primo Research Assistant (PR Newswire)
03:00AM	Clarivate Announces 15th Annual Pharmavision India Conference Agenda (PR Newswire)
Sep-14-24 11:23AM	Goldman Thinks Clarivate Plc (CLVT) Is A Long-Term AI Stock Set To Rally Eventually (Insider Monkey)
Sep-09-24 03:00AM	Clarivate Report Unveils the Transformative Role of Artificial Intelligence on Shaping the Future of the Library (PR Newswire)
Sep-05-24 09:00AM	Clarivate to Present at the Goldman Sachs Communacopia + Technology Conference on September 12 (PR Newswire)
Sep-04-24 03:00AM	Clarivate Launches Generative AI-Powered Web of Science Research Assistant (PR Newswire)
Aug-20-24 03:00AM	Clarivate Names Melanie Margolin as Chief Administrative and Legal Officer (PR Newswire)
Aug-07-24 08:15AM	Clarivate to Present at the Oppenheimer 27th Annual Technology, Internet & Communications Virtual Conference on August 12 (PR Newswire) -5.93%
Aug-06-24 12:33PM	Analyst Report: Clarivate Plc (Morningstar Research) -12.20%
06:01AM	Clarivate Appoints Former ProQuest CEO Matti Shem Tov as the Company's Next CEO (PR Newswire)
06:00AM	Clarivate Reports Second Quarter 2024 Results (PR Newswire)
Aug-05-24 06:40PM	Analyst Report: Clarivate Plc (Morningstar Research)
Jul-30-24 03:00AM	Clarivate Introduces New OFF-X Platform for Preclinical and Clinical Safety Intelligence (PR Newswire)
Jul-25-24 06:30PM	Analyst Report: Clarivate Plc (Morningstar Research)
Jul-24-24 07:30AM	Clarivate Director Richard Roedel to Retire from Board of Directors (PR Newswire)
Jul-22-24 06:00AM	Clarivate Acquires Rowan TELS to Enhance Support for Patent Practitioners (PR Newswire)
Jul-18-24 03:00AM	Clarivate to Partner with OhioLINK and SearchOhio to Create a New Unified Library Experience Across the State of Ohio (PR Newswire)
03:00AM	BioWorld by Clarivate Celebrates Nine Wins at 2024 APEX Awards (PR Newswire)
Jul-16-24 09:00AM	Clarivate to Report Second Quarter 2024 Results on August 6, 2024 (PR Newswire) +6.04%
03:00AM	Clarivate Annual G20 Scorecard Examines Global Research and Innovation Trends Across G20 Members (PR Newswire)
Jul-11-24 05:34AM	Should You Consider Adding Clarivate Plc (CLVT) to Your Portfolio? (Insider Monkey)
03:40AM	Should You Invest in Red Violet (RDVT)? (Insider Monkey)
Jul-10-24 04:00AM	Clarivate Reveals First Year of Unitary Patent Court Litigation Activity (PR Newswire)
Jul-02-24 03:00AM	Clarivate Identifies Six Breakthrough MedTech Trends in 2024 Set to Unlock New Industry Opportunities (PR Newswire)
Jun-27-24 06:15AM	Clarivate Report Demonstrates Societal Impact of Digital Health Research and Innovation Growth (PR Newswire)
Jun-25-24 11:51PM	Clarivate Plc (CLVT): The Best AI Stock to Buy Under $10? (Insider Monkey)
Jun-24-24 03:00AM	Clarivate Launches IP Collaboration Hub (PR Newswire)
Jun-20-24 03:00AM	Clarivate Reveals World's Leading and Trusted Journals with the 2024 Journal Citation Reports (PR Newswire)
Jun-19-24 03:00AM	Clarivate Identifies Seven Innovators in Antibody Drug Conjugates in New Companies to Watch Report (PR Newswire)
Jun-08-24 10:08PM	Top 50 Companies in London (Insider Monkey)
Jun-04-24 03:00AM	Clarivate Launches Research Horizon Navigator to Pinpoint Future Breakthrough Areas (PR Newswire)
May-31-24 03:00AM	Clarivate Expands Real-World Data Offering with Addition of Social Determinant of Health (SDoH) Attributes from HealthWise Data (PR Newswire)
May-30-24 05:15PM	Clarivate Announces Conversion Date and Conversion Rate for Series A Mandatory Convertible Preferred Shares (PR Newswire)
03:00AM	Clarivate Celebrates 500 Institutions Adopting Rialto Marketplace Solution (PR Newswire)
May-29-24 09:15AM	Clarivate to Present at Upcoming Investor Conferences in June 2024 (PR Newswire)
May-22-24 03:00AM	Clarivate Identifies Five Breakthrough Medical Technologies Set to Transform Patient Care in 2024 (PR Newswire)
May-21-24 03:00AM	New Clarivate Report Indicates Solid Growth in 2024 Global Trademark Filing Activity (PR Newswire)
May-20-24 03:00AM	Clarivate Launches AI-Enhanced Solution to Accelerate Trademark Watching (PR Newswire)
May-16-24 03:00AM	New Clarivate Report Reveals that the U.S., Germany and Mainland China have the most Non-Practicing Entity Litigation (PR Newswire)
May-15-24 03:56PM	Klarman's Baupost Group Buys Stake in SoundHound, Cuts Position in Warner Bros Discovery (Investopedia)
May-09-24 04:49AM	Analyst Report: Clarivate Plc (Morningstar Research)
03:00AM	OMRON Selects IPfolio from Clarivate (PR Newswire)
May-08-24 06:55PM	Analyst Report: Clarivate Plc (Morningstar Research) -11.37%
09:30AM	Compared to Estimates, Clarivate (CLVT) Q1 Earnings: A Look at Key Metrics (Zacks)
07:15AM	Clarivate PLC (CLVT) Q1 Earnings Meet Estimates (Zacks)
06:39AM	Clarivate Posts Loss In Q1; Reaffirms FY24 Outlook (RTT News)
06:00AM	Clarivate Reports First Quarter 2024 Results (PR Newswire)
May-07-24 03:00AM	Clarivate Introduces Epidemiology Intelligence for Precision Patient Population Analysis (PR Newswire)
May-02-24 03:00AM	Clarivate Enhances Cortellis CMC Intelligence with Post-Approval Module to Accelerate Regulatory Success (PR Newswire)
May-01-24 04:05PM	Clarivate Declares Dividend on Mandatory Convertible Preferred Shares (PR Newswire)
12:41PM	Koninklijke Philips N.V. (NYSE:PHG) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:01AM	Clarivate PLC (CLVT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-30-24 03:00AM	BioWorld by Clarivate Explores the Future of CAR T Therapy in Mainland China in Special Report (PR Newswire)
Apr-24-24 03:00AM	Clarivate joins United Nations SDG Publishers Compact (PR Newswire)
Apr-23-24 07:00AM	Clarivate Acquires Global QMS, Inc., Expanding Life Sciences & Healthcare Segment into New Markets (PR Newswire)

Clarivate Plc engages in the provision of global information, analytics, and workflow solutions. It operates through the following segments: Academia and Government (A&G), Intellectual Property (IP), and Life Sciences and Healthcare (LS&H). The A&G segment involves the provision of research and analytics, content aggregation, and workflow software solutions using artificial intelligence. The IP segment includes the maintenance, intelligence, and management solutions. The LS&H focuses on solutions for research and development, regulatory and safety, and commercialization. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pritchett Wendell E.	Director	Mar 03 '25	Buy	4.38	22,857	100,114	71,835	Mar 05 04:17 PM
SAHA SAURABH	Director	Mar 03 '25	Buy	4.36	58,275	254,079	82,016	Mar 05 04:17 PM
Angelakis Michael J	Director	Nov 20 '24	Buy	5.11	1,500,000	7,665,000	1,500,000	Nov 22 06:28 PM
Angelakis Michael J	Director	Nov 21 '24	Buy	5.19	1,200,000	6,228,000	2,700,000	Nov 22 06:28 PM
Angelakis Michael J	Director	Nov 22 '24	Buy	5.19	765,000	3,970,350	3,465,000	Nov 22 06:28 PM
Veinstein Bar	President, A&G	Oct 15 '24	Sale	7.00	60,000	420,000	916,583	Oct 17 04:19 PM
BAR VEINSTEIN	Officer	Oct 15 '24	Proposed Sale	7.00	60,000	420,000		Oct 15 04:34 PM
Veinstein Bar	President, A&G	Sep 19 '24	Sale	7.00	120,000	840,000	976,583	Sep 23 04:29 PM
BAR VEINSTEIN	Officer	Sep 19 '24	Proposed Sale	7.00	120,000	840,000		Sep 19 04:01 PM
SAHA SAURABH	Director	Aug 30 '24	Sale	6.75	17,646	119,110	23,741	Sep 04 04:51 PM
SAHA SAURABH	Director	Aug 30 '24	Proposed Sale	6.75	17,646	119,110		Aug 30 05:05 PM
Snyder Andrew Miles	Director	Aug 09 '24	Buy	5.67	262,000	1,485,540	550,334	Aug 12 04:30 PM
Snyder Andrew Miles	Director	Aug 08 '24	Buy	5.49	28,938	158,870	288,334	Aug 12 04:30 PM

Dollar change +0.22
Percentage change 1.34	%

CNTA Centessa Pharmaceuticals plc ADR daily Stock Chart

Peers: VRTX REGN MRNA BMRN IONS ALNY SRPT NBIX INCY ZLAB

| Held by: IBB GWX ONEQ BIB BBC IBBQ FPXE

Index	-	P/E	-	EPS (ttm)	-1.53	Insider Own	39.43%	Shs Outstand	131.66M	Perf Week	-1.59%
Market Cap	2.20B	Forward P/E	-	EPS next Y	-1.54	Insider Trans	-1.73%	Shs Float	79.75M	Perf Month	-6.18%
Income	-162.05M	PEG	-	EPS next Q	-0.42	Inst Own	55.19%	Short Float	6.84%	Perf Quarter	-10.61%
Sales	6.91M	P/S	318.00	EPS this Y	2.83%	Inst Trans	7.55%	Short Ratio	6.97	Perf Half Y	11.79%
Book/sh	3.79	P/B	4.40	EPS next Y	-1.24%	ROA	-32.83%	Short Interest	5.46M	Perf Year	51.31%
Cash/sh	3.94	P/C	4.24	EPS next 5Y	-3.40%	ROE	-42.73%	52W Range	7.75 - 19.09	Perf YTD	-0.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-27.78%	52W High	-12.57%	Beta	1.43
Dividend TTM	-	Quick Ratio	21.52	Sales past 5Y	0.00%	Gross Margin	86.07%	52W Low	115.35%	ATR (14)	1.13
Dividend Ex-Date	-	Current Ratio	21.52	EPS Y/Y TTM	7.72%	Oper. Margin	-2350.25%	RSI (14)	52.07	Volatility	6.37% 7.70%
Employees	76	Debt/Eq	0.17	Sales Y/Y TTM	-	Profit Margin	-2344.26%	Recom	1.00	Target Price	29.14
Option/Short	Yes / Yes	LT Debt/Eq	0.17	EPS Q/Q	6.97%	Payout	-	Rel Volume	1.46	Prev Close	16.47
Sales Surprise	-	EPS Surprise	6.64%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	783.52K	Price	16.69
SMA20	2.25%	SMA50	1.21%	SMA200	17.51%	Trades		Volume	344,197	Change	1.34%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-25	Initiated	TD Cowen	Buy
Sep-20-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$11 → $26
Sep-19-24	Initiated	B. Riley Securities	Buy	$33
Jul-18-24	Initiated	Oppenheimer	Outperform	$14
Nov-15-23	Upgrade	Jefferies	Hold → Buy	$4 → $11
Oct-26-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$4 → $8
Jun-21-23	Initiated	Evercore ISI	Outperform
Jun-12-23	Initiated	Guggenheim	Buy	$9
Mar-17-23	Initiated	SVB Securities	Outperform	$6
Aug-12-22	Downgrade	Morgan Stanley	Overweight → Underweight	$10 → $5
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$19
Jun-03-22	Downgrade	Jefferies	Buy → Hold	$37 → $4
Feb-11-22	Initiated	Goldman	Neutral	$12

Show Previous Ratings

Mar-06-25 04:14PM	Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Jan-28-25 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-13-25 09:51AM	Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20? (Insider Monkey)
Jan-09-25 05:14PM	Is Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25? (Insider Monkey)
Jan-08-25 07:05AM	Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer (GlobeNewswire) -7.04%
10:31AM	Loading…
Dec-20-24 10:31AM	Why Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday? (Insider Monkey)
Nov-13-24 06:15AM	Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing (BioPharma Dive) +6.35%
Nov-12-24 07:00AM	Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update (GlobeNewswire)
Nov-04-24 07:30AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-12-24 10:18AM	Centessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage Biotech (Insider Monkey)
Oct-09-24 08:04AM	Analysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising Developments (Insider Monkey)
Sep-26-24 06:00AM	Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) (GlobeNewswire)
Sep-12-24 10:34PM	Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares (GlobeNewswire) +9.82% +12.52%
Sep-11-24 04:04PM	Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares (GlobeNewswire) -5.69%
Sep-10-24 04:34PM	Centessa Reverses Lower Despite $5 Billion Narcolepsy Opportunity (Investor's Business Daily)
12:19PM	Loading…
12:19PM	Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers (Benzinga)
11:18AM	Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity (Investor's Business Daily)
08:15AM	Investors are waking up to Centessas sleepiness drug (BioPharma Dive)
07:00AM	Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers (GlobeNewswire)
Aug-27-24 08:00AM	Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) (GlobeNewswire)
Aug-24-24 01:18AM	Insider Sale: Chief Business Officer Gregory Weinhoff Sells 30,000 Shares of Centessa ... (GuruFocus.com)
Aug-21-24 08:00AM	Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-13-24 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 (GlobeNewswire)
Jul-16-24 09:55AM	Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade (Zacks)
Jun-13-24 09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
Jun-10-24 07:00AM	Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer (GlobeNewswire)
May-28-24 09:35AM	Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA) (Zacks)
May-21-24 08:45AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-13-24 09:54PM	CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:10PM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 (GlobeNewswire)
04:47AM	Loading…
Apr-24-24 04:47AM	Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS (MT Newswires)
Apr-23-24 09:36PM	Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares (GlobeNewswire) -6.00%
06:00PM	Centessa Pharmaceuticals Eyes $100 Million in ADS Offering (MT Newswires)
04:17PM	Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares (GlobeNewswire)
Apr-22-24 07:00AM	Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 (GlobeNewswire) -5.39%
Mar-28-24 11:53PM	CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
06:11PM	Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results (GuruFocus.com)
04:28PM	Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 (GlobeNewswire)
Mar-27-24 01:26AM	Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares (GuruFocus.com)
Mar-18-24 08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace) +5.18%
Feb-22-24 08:00AM	Centessa Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 07:00AM	Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (GlobeNewswire) +24.13%
Jan-22-24 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Dec-13-23 08:00AM	Centessa Pharmaceuticals to Present at the 42 Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-23 12:05PM	Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia (GlobeNewswire)
Dec-05-23 09:55AM	Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect? (Zacks)
Nov-27-23 04:15PM	Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals (GlobeNewswire) -7.69%
Nov-16-23 09:55AM	Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know (Zacks)
Nov-14-23 07:28PM	Centessa Pharmaceuticals PLC Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) +6.25% +8.75%
Nov-13-23 04:05PM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023 (GlobeNewswire)
Nov-02-23 09:09AM	Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-23 08:00AM	Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors (GlobeNewswire)
Oct-30-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.32%
Oct-25-23 08:00AM	Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders (GlobeNewswire) -6.02%
Oct-03-23 08:00AM	Centessa Pharmaceuticals Announces Additions to Senior Leadership Team (GlobeNewswire)
Sep-04-23 10:51AM	Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why (Zacks)
Aug-31-23 08:00AM	Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire) +6.35%
Aug-23-23 05:08PM	Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress (GlobeNewswire)
Aug-14-23 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023 (GlobeNewswire)
Jul-10-23 08:00AM	Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors (GlobeNewswire) +5.04%
May-24-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-22-23 07:00AM	Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B (GlobeNewswire)
May-12-23 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 (GlobeNewswire)
Apr-27-23 12:07PM	Centessa Pharmaceuticals plc (NASDAQ:CNTA) most popular amongst private equity firms who own 42% of the shares, institutions hold 22% (Simply Wall St.) -5.71%
Mar-30-23 07:00AM	Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022 (GlobeNewswire)
Mar-27-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-23-23 04:30PM	Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director (PR Newswire) +5.04%
08:32AM	Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings? (Zacks)
Mar-01-23 08:00AM	Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines (GlobeNewswire)
Feb-06-23 08:00AM	Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (GlobeNewswire)
Feb-02-23 08:00AM	Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-26-23 09:08AM	Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors (GlobeNewswire)
Dec-10-22 03:30PM	Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia (GlobeNewswire)
Nov-30-22 08:00AM	Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson (GlobeNewswire)
Nov-18-22 10:29AM	While institutions own 29% of Centessa Pharmaceuticals plc (NASDAQ:CNTA), private equity firms are its largest shareholders with 42% ownership (Simply Wall St.)
Nov-10-22 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022 (GlobeNewswire)
Nov-03-22 09:04AM	Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting (GlobeNewswire)
Oct-31-22 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-20-22 08:33AM	Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022) (GlobeNewswire)
Sep-14-22 09:00AM	Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B (GlobeNewswire) +8.92%
Sep-12-22 07:00AM	Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index (GlobeNewswire)
Aug-29-22 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-22 08:37AM	Centessa Culls Early-Stage Asset For Inherited Disorder (Benzinga) -5.19%
06:30AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874 (GlobeNewswire)
Jul-29-22 05:00AM	Why are Massachusetts CEOs paid so much money? Here's a primer (American City Business Journals)
Jul-25-22 08:00AM	Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs (GlobeNewswire)
Jul-01-22 08:40AM	Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors (GlobeNewswire) +6.16%
Jun-23-22 09:55AM	Wall Street Analysts Predict a 128% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know (Zacks)
Jun-17-22 02:35PM	BMO Capital Sees Almost 300% Upside On Centessa Stock (Benzinga) +19.08%
Jun-11-22 10:06AM	What Kind Of Investors Own Most Of Centessa Pharmaceuticals plc (NASDAQ:CNTA)? (Simply Wall St.)
Jun-06-22 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-05-22 07:00AM	Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting (GlobeNewswire)
Jun-03-22 08:29AM	Record-Setting Biotech Plunges 25% After Axing Lead Program (TheStreet.com)
Jun-02-22 06:29AM	Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) (GlobeNewswire) -27.78%
May-16-22 07:00AM	Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-30-22 04:01PM	Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-23-22 04:30PM	Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day (GlobeNewswire)
Mar-07-22 07:30AM	Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise (GlobeNewswire)
Feb-24-22 07:30AM	Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease (GlobeNewswire)
Feb-17-22 02:38AM	Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs Samsara BioCapital (Insider Monkey)

Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Weinhoff Gregory M	Chief Business Officer	Feb 25 '25	Sale	15.25	11,494	175,270	134,021	Feb 26 04:24 PM
Weinhoff Gregory M	Officer	Feb 25 '25	Proposed Sale	15.25	11,494	175,270		Feb 25 04:03 PM
SAHA SAURABH	Chief Executive Officer	Feb 20 '25	Sale	15.93	55,000	876,088	331,017	Feb 20 05:45 PM
SAHA SAURABH	Officer	Feb 20 '25	Proposed Sale	15.90	55,000	874,500		Feb 20 04:14 PM
HUSSAIN IQBAL J	General Counsel	Feb 18 '25	Option Exercise	5.84	6,000	35,040	111,386	Feb 19 05:59 PM
HUSSAIN IQBAL J	General Counsel	Feb 18 '25	Sale	16.18	6,000	97,065	105,386	Feb 19 05:59 PM
HUSSAIN IQBAL J	Officer	Feb 18 '25	Proposed Sale	17.07	6,000	102,420		Feb 18 04:05 PM
Anderson Karen M.	Chief People Officer	Feb 07 '25	Option Exercise	4.01	30,526	122,409	84,848	Feb 10 05:33 PM
Anderson Karen M.	Chief People Officer	Feb 10 '25	Option Exercise	4.01	429	1,720	54,751	Feb 10 05:33 PM
Anderson Karen M.	Chief People Officer	Feb 07 '25	Sale	19.03	30,526	580,797	54,322	Feb 10 05:33 PM
Anderson Karen M.	Chief People Officer	Feb 10 '25	Sale	18.99	429	8,147	54,322	Feb 10 05:33 PM
Anderson Karen M.	Officer	Feb 10 '25	Proposed Sale	18.99	429	8,147		Feb 10 04:14 PM
Anderson Karen M.	Officer	Feb 07 '25	Proposed Sale	19.03	30,526	580,797		Feb 07 04:13 PM
Anderson Karen M.	Chief People Officer	Feb 03 '25	Sale	16.86	6,471	109,124	54,322	Feb 04 04:56 PM
Bush Tia L	Chief Technology & Quality Ofc	Feb 03 '25	Sale	16.86	11,000	185,406	121,503	Feb 04 04:55 PM
Bush Tia L	Officer	Feb 03 '25	Proposed Sale	16.49	11,000	181,390		Feb 03 04:08 PM
Anderson Karen M.	Officer	Feb 03 '25	Proposed Sale	16.49	6,471	106,707		Feb 03 04:04 PM
Weinhoff Gregory M	Chief Business Officer	Jan 27 '25	Sale	16.47	11,742	193,429	159,782	Jan 28 04:32 PM
Weinhoff Gregory M	Officer	Jan 27 '25	Proposed Sale	16.47	11,742	193,429		Jan 27 04:07 PM
SAHA SAURABH	Chief Executive Officer	Jan 21 '25	Sale	15.77	55,000	867,430	429,398	Jan 22 04:15 PM
SAHA SAURABH	Officer	Jan 21 '25	Proposed Sale	15.29	55,000	840,950		Jan 21 04:07 PM
HUSSAIN IQBAL J	General Counsel	Jan 15 '25	Option Exercise	5.84	6,000	35,040	124,265	Jan 17 04:15 PM
HUSSAIN IQBAL J	General Counsel	Jan 15 '25	Sale	15.29	6,000	91,740	118,265	Jan 17 04:15 PM
HUSSAIN IQBAL J	Officer	Jan 15 '25	Proposed Sale	15.12	6,000	90,720		Jan 15 04:06 PM
Weinhoff Gregory M	Chief Business Officer	Dec 26 '24	Option Exercise	3.85	10,000	38,500	193,266	Dec 26 06:10 PM
Weinhoff Gregory M	Chief Business Officer	Dec 26 '24	Sale	17.04	10,000	170,399	183,266	Dec 26 06:10 PM
Weinhoff Gregory M	Officer	Dec 26 '24	Proposed Sale	16.80	10,000	168,000		Dec 26 04:02 PM
SAHA SAURABH	Chief Executive Officer	Dec 20 '24	Sale	17.44	55,000	959,057	520,661	Dec 20 05:22 PM
SAHA SAURABH	Officer	Dec 20 '24	Proposed Sale	17.55	55,000	965,250		Dec 20 04:18 PM
Bush Tia L	Chief Technology & Quality Ofc	Dec 17 '24	Option Exercise	3.85	17,813	68,580	165,428	Dec 17 05:11 PM
Bush Tia L	Chief Technology & Quality Ofc	Dec 17 '24	Sale	18.00	17,813	320,634	147,615	Dec 17 05:11 PM
Bush Tia L	Chief Technology & Quality Ofc	Dec 16 '24	Sale	16.36	9,611	157,256	147,615	Dec 17 05:11 PM
HUSSAIN IQBAL J	General Counsel	Dec 16 '24	Option Exercise	5.84	6,000	35,040	203,490	Dec 17 05:10 PM
HUSSAIN IQBAL J	General Counsel	Dec 16 '24	Sale	16.39	77,705	1,273,756	125,785	Dec 17 05:10 PM
Anderson Karen M.	Chief People Officer	Dec 17 '24	Option Exercise	3.85	10,624	40,902	82,149	Dec 17 05:09 PM
Anderson Karen M.	Chief People Officer	Dec 13 '24	Option Exercise	3.85	5,876	22,623	77,401	Dec 17 05:09 PM
Anderson Karen M.	Chief People Officer	Dec 17 '24	Sale	17.32	10,624	184,036	71,525	Dec 17 05:09 PM
Anderson Karen M.	Chief People Officer	Dec 13 '24	Sale	17.01	5,876	99,974	71,525	Dec 17 05:09 PM
Bush Tia L	Officer	Dec 17 '24	Proposed Sale	18.00	17,813	320,634		Dec 17 04:02 PM
HUSSAIN IQBAL J	Officer	Dec 16 '24	Proposed Sale	16.57	77,705	1,287,572		Dec 16 04:14 PM
Bush Tia L	Officer	Dec 16 '24	Proposed Sale	16.57	9,611	159,254		Dec 16 04:04 PM
Anderson Karen M.	Officer	Dec 13 '24	Proposed Sale	16.89	16,500	278,685		Dec 13 04:03 PM
SAHA SAURABH	Chief Executive Officer	Dec 06 '24	Option Exercise	5.84	87,496	510,977	663,157	Dec 06 05:03 PM
SAHA SAURABH	Chief Executive Officer	Dec 06 '24	Sale	18.46	87,496	1,615,255	575,661	Dec 06 05:03 PM
SAHA SAURABH	Officer	Dec 06 '24	Proposed Sale	18.46	87,496	1,615,255		Dec 06 04:14 PM
SAHA SAURABH	Chief Executive Officer	Nov 25 '24	Option Exercise	5.84	299	1,746	575,960	Nov 27 04:22 PM
SAHA SAURABH	Chief Executive Officer	Nov 25 '24	Sale	18.23	299	5,451	575,661	Nov 27 04:22 PM
Weinhoff Gregory M	Chief Business Officer	Nov 25 '24	Option Exercise	3.85	10,000	38,500	193,266	Nov 27 04:20 PM
Weinhoff Gregory M	Chief Business Officer	Nov 25 '24	Sale	17.66	10,000	176,601	183,266	Nov 27 04:20 PM
Weinhoff Gregory M	Officer	Nov 25 '24	Proposed Sale	17.39	10,000	173,900		Nov 25 04:07 PM
SAHA SAURABH	Officer	Nov 25 '24	Proposed Sale	34.95	299	10,451		Nov 25 04:03 PM
SAHA SAURABH	Chief Executive Officer	Nov 21 '24	Option Exercise	5.84	3,511	20,504	579,172	Nov 22 05:06 PM
SAHA SAURABH	Chief Executive Officer	Nov 22 '24	Option Exercise	5.84	1,671	9,759	577,332	Nov 22 05:06 PM
SAHA SAURABH	Chief Executive Officer	Nov 20 '24	Sale	16.89	55,000	928,719	575,661	Nov 22 05:06 PM
SAHA SAURABH	Chief Executive Officer	Nov 21 '24	Sale	18.24	3,511	64,028	575,661	Nov 22 05:06 PM
SAHA SAURABH	Chief Executive Officer	Nov 22 '24	Sale	18.24	1,671	30,478	575,661	Nov 22 05:06 PM
SAHA SAURABH	Officer	Nov 22 '24	Proposed Sale	18.23	1,671	30,462		Nov 22 04:03 PM
SAHA SAURABH	Officer	Nov 21 '24	Proposed Sale	18.24	3,511	64,028		Nov 21 04:33 PM
SAHA SAURABH	Officer	Nov 20 '24	Proposed Sale	16.97	55,000	933,350		Nov 20 04:03 PM
SAHA SAURABH	Chief Executive Officer	Nov 13 '24	Option Exercise	5.84	32,023	187,014	662,684	Nov 15 04:30 PM
SAHA SAURABH	Chief Executive Officer	Nov 13 '24	Sale	18.28	32,023	585,419	630,661	Nov 15 04:30 PM
SAHA SAURABH	Officer	Nov 13 '24	Proposed Sale	18.28	32,023	585,418		Nov 13 04:18 PM
Weinhoff Gregory M	Chief Business Officer	Oct 25 '24	Sale	15.38	11,742	180,628	183,266	Oct 25 07:19 PM
Weinhoff Gregory M	Officer	Oct 25 '24	Proposed Sale	15.57	11,742	182,822		Oct 25 04:10 PM
SAHA SAURABH	Chief Executive Officer	Oct 22 '24	Sale	15.67	30,203	473,169	633,253	Oct 23 05:27 PM
SAHA SAURABH	Chief Executive Officer	Oct 21 '24	Sale	15.80	22,205	350,861	663,456	Oct 23 05:27 PM
SAHA SAURABH	Chief Executive Officer	Oct 23 '24	Sale	15.32	2,592	39,697	630,661	Oct 23 05:27 PM
SAHA SAURABH	Officer	Oct 23 '24	Proposed Sale	15.46	2,592	40,072		Oct 23 04:07 PM
SAHA SAURABH	Officer	Oct 22 '24	Proposed Sale	15.67	30,203	473,169		Oct 22 04:15 PM
SAHA SAURABH	Officer	Oct 21 '24	Proposed Sale	15.80	22,205	350,861		Oct 21 04:55 PM
Weinhoff Gregory M	Chief Business Officer	Sep 25 '24	Sale	15.69	16,619	260,724	206,750	Sep 27 04:15 PM
Weinhoff Gregory M	Officer	Sep 25 '24	Proposed Sale	15.80	16,619	262,580		Sep 25 04:01 PM
SAHA SAURABH	Chief Executive Officer	Sep 20 '24	Sale	16.53	55,000	908,985	721,924	Sep 20 04:55 PM
SAHA SAURABH	Officer	Sep 20 '24	Proposed Sale	16.45	55,000	904,750		Sep 20 04:01 PM
Weinhoff Gregory M	Chief Business Officer	Sep 10 '24	Option Exercise	5.84	30,000	175,200	253,369	Sep 12 08:01 PM
Weinhoff Gregory M	Chief Business Officer	Sep 10 '24	Sale	17.00	30,000	510,000	223,369	Sep 12 08:01 PM
SAHA SAURABH	Chief Executive Officer	Sep 10 '24	Option Exercise	5.84	175,000	1,022,000	951,924	Sep 12 08:01 PM
SAHA SAURABH	Chief Executive Officer	Sep 10 '24	Sale	16.52	175,000	2,891,822	776,924	Sep 12 08:01 PM
SAHA SAURABH	Officer	Sep 10 '24	Proposed Sale	16.52	175,000	2,891,822		Sep 10 04:06 PM
Weinhoff Gregory M	Officer	Sep 10 '24	Proposed Sale	17.00	30,000	510,000		Sep 10 04:04 PM
Weinhoff Gregory M	Chief Business Officer	Sep 09 '24	Option Exercise	5.84	25,000	146,000	248,369	Sep 09 05:06 PM
Weinhoff Gregory M	Chief Business Officer	Sep 09 '24	Sale	15.00	25,000	375,000	223,369	Sep 09 05:06 PM
Weinhoff Gregory M	Officer	Sep 09 '24	Proposed Sale	15.00	25,000	375,000		Sep 09 04:07 PM
SAHA SAURABH	Chief Executive Officer	Aug 23 '24	Sale	12.30	46,651	573,905	776,924	Aug 23 05:13 PM
Weinhoff Gregory M	Chief Business Officer	Aug 23 '24	Sale	12.29	17,802	218,792	223,369	Aug 23 05:12 PM
Weinhoff Gregory M	Chief Business Officer	Aug 22 '24	Sale	12.17	12,198	148,430	241,171	Aug 23 05:12 PM
Weinhoff Gregory M	Officer	Aug 23 '24	Proposed Sale	12.29	17,802	218,792		Aug 23 04:19 PM
SAHA SAURABH	Officer	Aug 23 '24	Proposed Sale	12.30	46,651	573,905		Aug 23 04:13 PM
SAHA SAURABH	Chief Executive Officer	Aug 20 '24	Sale	12.32	4,169	51,368	827,755	Aug 22 05:15 PM
SAHA SAURABH	Chief Executive Officer	Aug 21 '24	Sale	12.25	3,674	44,989	824,081	Aug 22 05:15 PM
SAHA SAURABH	Chief Executive Officer	Aug 22 '24	Sale	12.23	506	6,188	823,575	Aug 22 05:15 PM
Weinhoff Gregory M	Officer	Aug 22 '24	Proposed Sale	12.24	12,198	149,304		Aug 22 04:32 PM
SAHA SAURABH	Officer	Aug 22 '24	Proposed Sale	12.23	506	6,188		Aug 22 04:13 PM
SAHA SAURABH	Officer	Aug 21 '24	Proposed Sale	12.25	3,674	44,989		Aug 21 04:38 PM
SAHA SAURABH	Officer	Aug 20 '24	Proposed Sale	12.32	4,169	51,368		Aug 20 04:52 PM
Anderson Karen M.	Chief People Officer	Mar 25 '24	Option Exercise	3.94	45,000	177,252	122,685	Mar 26 04:16 PM
Anderson Karen M.	Chief People Officer	Mar 25 '24	Sale	11.88	51,160	607,960	71,525	Mar 26 04:16 PM

CLVT

Clarivate Plc

CNTA

Centessa Pharmaceuticals plc ADR

Upgrade your FINVIZ experience